|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **All Patients**  **N=59** | **Part I Total**  **N=29** | **Part II Total**  **N=30** | **Part II Cohort A**  **N=28** |
| Afuresertib daily dose, mg | 117.30  (41.5‒142.0) | 106.00  (41.5‒136.9) | 125.00  (60.0‒142.0) | 124.85  (60.0‒142.0) |
| Time on afuresertib treatment, months | 6.10 (0.2‒13.2) | 5.70 (0.2‒10.4) | 6.55 (0.2‒13.2) | 6.55 (0.2‒13.2) |
| Dose intensity of paclitaxel,  mg/week | 89.30  (42.2‒123.3) | 88.80 (42.2‒110.8) | 89.95  (62.0‒123.3) | 89.95 (62.0‒123.3) |
| Dose intensity of carboplatin, mg/week | 150.40  (63.1‒231.8) | 144.00  (63.1‒200.0) | 152.95  (76.9‒231.8) | 152.95  (76.9‒231.8) |
| Cycles of paclitaxel, n | 6.0 (1‒6) | 5.0 (1‒6) | 6.0 (1‒6) | 6.0 (1‒6) |
| Cycles of carboplatin, n | 6.0 (1‒6) | 6.0 (1‒6) | 6.0 (1‒6) | 6.0 (1‒6) |

**Supplemental Table S1.** Summary of exposure to afuresertib, paclitaxel and carboplatin (ITT population).

All data are presented as median (range) values.